NCT03659448: A trial that was reported late by Surgimab
This trial has reported, although it was 121 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03659448 |
|---|---|
| Title | Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 17, 2019 |
| Completion date | Nov. 30, 2024 |
| Required reporting date | Nov. 30, 2025, midnight |
| Actual reporting date | March 31, 2026 |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | 121 |